Today's Top Gainer
| SYMBOL | CMP | Chg (%) |
|---|---|---|
Note:Top Gainer - Nifty 50 More
Authors
-
Nirmal JainChairman, IIFL -
R. VenkataramanManaging Director, IIFL -
Abhimanyu SofatHead of Research, IIFL Securities -
Amar AmbaniHead - Research, IIFL -
Amar ChoudharyCEO & Co Founder, FinAskus -
Anil PharandeChairman -
Ankur ChoudharyCIO and Co-Founder, Goalwise -
Ankur VishnoiDerivative Analyst, IIFL Derivative Desk -
Anuj PuriChairman, ANAROCK Property Consultants -
Anuraag SabooCo-Founder & CEO, FundExpert -
Aparna HariSenior Manager - Corporate Communications, FundsIndia -
Devansh MehtaSenior Investment Advisor, IIFL -
Dharmesh JainPresident, MCHI-CREDAI and CMD, Nirmal Lifestyle -
Dr. Sunil GuptaFormer Director of PNB and Dena Bank -
Gunjan GoelDirector, Goel Ganga Developments -
Hadrien MendoncaSenior Technical Analyst, IIFL -
Harjot Singh NarulaFounder & CEO, ComparePolicy -
Harsh Vardhan SinghCo-founder & CEO, Tauro Investment Advisors -
Hitesh JainHead of Alternate Research -
Jasjeet SinghPartner – Financial Services Analytics, Advisory – EY India -
Jayesh BhanushaliSenior Derivative Analyst, IIFL -
JC SharmaVC and MD, Sobha Limited -
Jenny DaleyPresident and CEO, Omega Performance -
Jitender SinghDeputy Manager-Research, IIFL -
Johann VaucansonManaging Director, Edenred India -
Kishor PateCMD, Amit Enterprises Housing Ltd. -
Krunali ShahContent Writer, IIFL Securities -
M. RavichandranPresident – Insurance, TATA AIG General Insurance Company Limited -
Mandeep LambaManaging Director - Hotels, JLL India -
Manish BatwaraDeputy Vice President E- Broking India Private Client, IIFL -
Manish HermajaniCOO & Co-Founder, FinAskus -
Marek MachalaHead of Online, Home Credit India -
Mark StorrieSenior Underwriter - M&A, AIG -
Mohit SinghCBO, Finaskus -
Murali IyerIIFL -
Murali MalayappanManaging Director, Shriram Properties -
NarayanFounder & President, Integron India -
Naseem JavedChairman, Mentorian Worldwide -
Neel VyasSenior Investment Advisor, IIFL -
Nitin MishraSenior Vice-President – Products and Services, Netmagic -
Prashant TripathySenior Director and CFO, Max Life Insurance -
Pratik SealGroup CMO, AGS Transact Technologies -
Pritesh MehtaHead of Technicals Research, IIFL -
Rajas PednekarBlogger, IIFL -
Rajesh SudExecutive Vice Chairman & Managing Director, Max Life Insurance -
Rajiv RajCo-Founder & Director -
Ramesh NairCEO & Country Head, JLL India -
Raushan KumarDerivative Analyst, IIFL Derivative Desk -
Riddhi VyasContent Manager, IIFL Securities -
Ritesh PatelCommodity Analyst, IIFL Research -
Sachin BhardwajDirector, Marketing & Business Development -
Sachin ChandavarkarVice-President, New Initiatives -
SarabdeepCo-founder, bodhik -
Sharda TickooTechnical Head, Trend Micro India -
Shikha VermaAuthor & Seasoned Insurance Professional, ComparePolicy -
Shubhranshu PaniManaging Director - Strategic Consulting -
Siddharth ZarabiExecutive Editor, BTVi -
Soumitro ChakrabortyCEO, Fiinovation -
Subhajit BhattacharyaNews Editor, Dalal Street Investment Journal -
Sudhir RaikarContent Architect -
Sunny ChhabriaSouth Asia Sales Manager, Bloomberg LP -
Sushant SarinExecutive Vice President Commercial Lines, Tata AIG General Insurance -
Swati AggarwalCo-founder, ORO Wealth -
Tanuj KhoslaExecutive Member, CAIA Singapore -
Tarun MathurDirector of Life Insurance at Policybazaar -
Tejasvi MohanramCEO, RupeePower -
V ViswanandSenior Director & COO, Max Life Insurance -
Vidya BalaHead of Mutual Research, Fundsindia -
Vipin KhandelwalFounder, Unovest -
Yasser ZeineldinCEO, eHosting DataFort -
Yogesh MehraCEO & Co-founder, YOLO Homes -
Zoya BrarFounder and MD, Core Diagnostics
Categories
-
Riding the NCD wave
by Amar Ambani July 21, 2011 10:49 IST
NCDs have had notable success in recent history. Corporates are viewing this instrument as the best bet to raise funds and demand from retail and institutional investors is high. While there are inherent risks compared to bank FDs, post tax returns are attractive in many cases. Further, reputed issuers are securing these by a charge on company assets. A word of caution: Always check the credit rating and stay away from low rated paper and issuers with generic or vague fund-raising propositions.
- Page
- 1
-
Thyrocare’s high B2B exposure helps it procure reagent at ~70% discount, thereby protecting margins. The 24% revenue ...
Buy Reco. Price: 549.25
-
Syngene is moving up in the CRO value chain by expanding its research capabilities and foraying in API manufacturing in FY20E. ...
Accumulate Reco. Price: 566.65